MedPath

What is the ED95 dose of Prilocaine for femoral nerve block using ultrasound?” - MED and femoral nerve block

Phase 1
Registration Number
EUCTR2008-008177-57-GB
Lead Sponsor
niversity of Leeds
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

•ASA 1-3 patients
•Age > 18 years
•Routine patients presenting for muscle biopsy

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•ASA > 3
•Age < 18 years
•Allergy to prilocaine
•Unable to give informed consent
•Body Mass Index > 35
•Patients on sulphonamides, antimalarials
•Pregnant woman

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To find out the ED95 of 1% prilocaine for femoral nerve block using ultrasound.;Secondary Objective: -;Primary end point(s): Assessment of effect of block to cold with an alcohol swab at the motor point of vastus medialis after femoral nerve block. The motor point of vastus medialis will be identified using a nerve stimulator after the femoral nerve block and is usually about 5 cm medial and cephalad to the knee cap. This does not hurt.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath